CAMBRIDGE, Massachusetts, August 21, 2026, 17:00 EDT — U.S. markets did not open.
- Moderna finished Friday at $145.13, gaining 8.86% on the day and rising 130.5% since Tuesday.
- The market value increased by around $32.81 billion over three sessions, which is close to five times June’s cash and investments.
- The share price is currently 69.8% higher than the average Wall Street target of $85.46.
Moderna, Inc. NASDAQ:MRNA closed its most turbulent week since the pandemic at $145.13. The stock rose 8.86% on Friday, following two days of sharp gains and losses. After-hours trading added a further 0.43%, bringing shares to $145.75.
The decision came after favorable topline Phase 3 data for intismeran, Moderna’s personalized cancer treatment. Combined with Merck & Co., Inc.’s NYSE:MRK Keytruda, the drug led to greater recurrence-free and distant-metastasis-free survival compared with Keytruda by itself in patients with resected melanoma.
The firms have yet to release hazard ratios or complete survival curves. Monitoring of overall survival is ongoing. This discrepancy is significant as Moderna’s valuation has increased much more rapidly than the publicly available data supports.
| Price path | Close | Daily move | Read-through |
|---|---|---|---|
| Tuesday, Aug. 18 | $62.96 | -2.33% | Final close ahead of Phase 3 results |
| Wednesday, Aug. 19 | $174.38 | +176.97% | Strong topline numbers drove pipeline revaluation |
| Thursday, Aug. 20 | $133.32 | -23.55% | Questions about valuation drove sell-off |
| Friday, Aug. 21 | $145.13 | +8.86% | Shares recovered part of Thursday’s losses |
Moderna’s share price rose $82.17, or 130.5%, from Tuesday’s close of $62.96. With 399.24 million shares outstanding, this translates to a roughly $32.81 billion increase in equity value. This figure is 4.8 times Moderna’s $6.9 billion in cash and investments reported for June.
The INTerpath-001 trial, involving 1,137 participants, achieved its main goal at a planned interim review. A significant secondary goal was met as well. The study did not report any new safety issues, and it will proceed to assess overall survival.
Moderna CEO Stéphane Bancel stated the company was “helping turn that vision into a reality.” Moderna and Merck intend to deliver complete data at an international medical conference, as well as consult with regulators about potential filings. Moderna IR Insights
| Evidence and economics | Verified figure | Investor implication |
|---|---|---|
| Phase 3 enrollment | 1,137 patients | Extensive randomized melanoma trial |
| Endpoints achieved | RFS and DMFS | Backs upcoming regulatory engagement |
| Specific Phase 3 effect size | Not yet disclosed | Scale of benefit has not been released publicly |
| Prior Phase 2b RFS data | 49% risk reduction | Contextual evidence, Phase 3 confirmation still needed |
| Trial pipeline | Nine Phase 2/3 studies | Program’s value linked to outcomes beyond melanoma |
| Partnership economics | 50/50 costs and profit | Moderna and Merck divide program economics |
UBS analysts provided a helpful valuation perspective, estimating that Wednesday’s price reflected a valuation of approximately $60 billion for intismeran, once a modest value was assigned to Moderna’s COVID business. According to UBS, achieving this would likely need annual therapy sales of around $20 billion. UBS maintained its $150 price target.
With Friday’s recovery, Moderna approached a key bullish short-term level. The stock also finished 69.8% higher than the $85.46 average target listed on Google Finance. The consensus rating is still Hold, with two analysts rating it Buy, 12 suggesting Hold, and one recommending Sell.
| Analyst | Firm | Rating | Target | Date |
|---|---|---|---|---|
| Alec Stranahan | Bank of America Securities | Hold | $170 | Aug. 19 |
| Michael Yee | UBS | Hold | $150 | Aug. 20 |
| Luca Issi | RBC Capital | Hold | $130 | Aug. 19 |
| Salveen Richter | Goldman Sachs | Hold | $120 | Aug. 19 |
| Jessica Fye | J.P. Morgan | Sell | $77 | Aug. 21 |
| 15-analyst consensus | Wall Street | Hold | $85.46 on average | Current |
The balance sheet provides breathing room, yet strong commercial performance remains crucial. Second-quarter revenue reached $145 million, with a net loss of $782 million. Cash and investments dropped to $6.9 billion, excluding a $950 million litigation payment made in July.
Merck gained 2.39% on Friday, closing at $152.55, showing a more modest movement. The difference highlights each company’s level of exposure. Intismeran represents just one project within Merck’s expansive oncology lineup, but it is now the primary valuation driver for Moderna.
Risks: Comprehensive Phase 3 results might reveal a benefit that is less than what is currently reflected in the share price. Regulators could require extended overall-survival tracking. Producing a personalized treatment may restrict profit margins, and Moderna’s economic interest is capped by the 50/50 Merck partnership.
The upcoming challenge is the presentation at a medical meeting. Investors await hazard ratios, confidence intervals, subgroup analyses and safety data. For now, Moderna’s $32.81 billion revaluation relies on endpoints where the effect size has not been revealed.
Related articles: NASDAQ:MRNA
![Australia Stock Market Today 08.22.2026 [UPDATE: 08.22.2026 08:37 AEST] [Weekly Recap and Week Ahead: Healthcare Leads, CPI Looms]](https://ts2.tech/wp-content/uploads/2026/08/AU-market-dashboard-2026-08-22-0837-480x384.jpg "Australia Stock Market Today 08.22.2026 [UPDATE: 08.22.2026 08:37 AEST] [Weekly Recap and Week Ahead: Healthcare Leads, CPI Looms]")
